JNJ
Johnson & Johnson
Quarterly revenue, EPS, free cash flow, valuation, and Rule of 40 scores for Johnson & Johnson.
Coverage
Strong Buy on JNJ at $228.26
Insiders cashing out 22.8M shares; technical target $148.29, consensus $230.63.
Johnson & Johnson Guidance
Guides significant oncology sales growth, potentially doubling near-term; supports strong long-term growth.
Biopharma Sentiment Snapped Higher
BPSI index jumped 78 to 90; aligns with price action and deal flow—continued M&A/IPOs expected.
Hospitals in Correction Mode
Stocks down 20-30%; focus on below 20x EV/EBITDA with 20%+ growth—structural tailwind intact.
Latest: $25.31B (2026Q2)
| Period | Value |
|---|---|
| 2020Q3 | $21.08B |
| 2020Q4 | $22.48B |
| 2021Q1 | $22.32B |
| 2021Q2 | $23.31B |
| 2021Q3 | $23.34B |
| 2021Q4 | $9.77B |
| 2022Q1 | $23.43B |
| 2022Q2 | $24.02B |
| 2022Q3 | $20.00B |
| 2022Q4 | $12.55B |
| 2023Q1 | $20.89B |
| 2023Q2 | $21.52B |
| 2023Q3 | $21.35B |
| 2023Q4 | $21.39B |
| 2024Q1 | $21.38B |
| 2024Q2 | $22.45B |
| 2024Q3 | $22.47B |
| 2024Q4 | $22.52B |
| 2025Q1 | $21.89B |
| 2025Q2 | $23.74B |
| 2025Q3 | $23.99B |
| 2025Q4 | $24.56B |
| 2026Q1 | $24.06B |
| 2026Q2 | $25.31B |
Latest: $2.27 (2026Q2)
| Period | Value |
|---|---|
| 2020Q3 | $1.33 |
| 2020Q4 | $0.65 |
| 2021Q1 | $2.32 |
| 2021Q2 | $2.35 |
| 2021Q3 | $1.37 |
| 2021Q4 | $1.77 |
| 2022Q1 | $1.93 |
| 2022Q2 | $1.80 |
| 2022Q3 | $1.68 |
| 2022Q4 | $1.32 |
| 2023Q1 | -$0.03 |
| 2023Q2 | $1.96 |
| 2023Q3 | $10.21 |
| 2023Q4 | $1.58 |
| 2024Q1 | $1.34 |
| 2024Q2 | $1.93 |
| 2024Q3 | $1.11 |
| 2024Q4 | $1.41 |
| 2025Q1 | $4.54 |
| 2025Q2 | $2.29 |
| 2025Q3 | $2.12 |
| 2025Q4 | $2.10 |
| 2026Q1 | $2.14 |
| 2026Q2 | $2.27 |
Latest: 28.3 (2026Q1)
| Period | Value |
|---|---|
| 2020Q2 | 17.6 |
| 2020Q3 | 20.2 |
| 2020Q4 | 24.8 |
| 2021Q1 | 25.4 |
| 2021Q2 | 21.8 |
| 2021Q3 | 21.3 |
| 2021Q4 | 19.5 |
| 2022Q1 | 21.4 |
| 2022Q2 | 23.3 |
| 2022Q3 | 20.6 |
| 2022Q4 | 23.9 |
| 2023Q1 | 29.8 |
| 2023Q2 | 31.0 |
| 2023Q3 | 10.8 |
| 2023Q4 | 10.7 |
| 2024Q1 | 9.3 |
| 2024Q2 | 8.7 |
| 2024Q3 | 22.6 |
| 2024Q4 | 21.1 |
| 2025Q1 | 18.0 |
| 2025Q2 | 16.1 |
| 2025Q3 | 17.8 |
| 2025Q4 | 18.7 |
| 2026Q1 | 28.3 |
Latest: $7.29B (2026Q2)
| Period | Value |
|---|---|
| 2020Q3 | $7.66B |
| 2020Q4 | $7.22B |
| 2021Q1 | $4.00B |
| 2021Q2 | $4.55B |
| 2021Q3 | $7.55B |
| 2021Q4 | $4.36B |
| 2022Q1 | $3.62B |
| 2022Q2 | $4.78B |
| 2022Q3 | $5.34B |
| 2022Q4 | $3.98B |
| 2023Q1 | $2.43B |
| 2023Q2 | $3.13B |
| 2023Q3 | $6.64B |
| 2023Q4 | $6.39B |
| 2024Q1 | $3.06B |
| 2024Q2 | $5.02B |
| 2024Q3 | $7.01B |
| 2024Q4 | $5.42B |
| 2025Q1 | $3.66B |
| 2025Q2 | $2.89B |
| 2025Q3 | $8.09B |
| 2025Q4 | $5.47B |
| 2026Q1 | $1.47B |
| 2026Q2 | $7.29B |
Latest: $2,409,295,102.00 (2025Q3)
| Period | Value |
|---|---|
| 2018Q1 | $2,682,149,964.00 |
| 2018Q2 | $2,682,756,061.00 |
| 2018Q3 | $2,681,977,969.00 |
| 2019Q1 | $2,655,055,987.00 |
| 2019Q2 | $2,639,165,527.00 |
| 2019Q3 | $2,631,872,399.00 |
| 2020Q1 | $2,634,594,535.00 |
| 2020Q2 | $2,632,823,475.00 |
| 2020Q3 | $2,632,542,672.00 |
| 2021Q1 | $2,633,396,003.00 |
| 2021Q2 | $2,632,482,092.00 |
| 2021Q3 | $2,632,596,969.00 |
| 2022Q1 | $2,631,401,804.00 |
| 2022Q2 | $2,629,179,895.00 |
| 2022Q3 | $2,614,483,607.00 |
| 2023Q1 | $2,598,734,075.00 |
| 2023Q2 | $2,598,969,594.00 |
| 2023Q3 | $2,407,278,620.00 |
| 2024Q1 | $2,406,679,183.00 |
| 2024Q2 | $2,407,243,667.00 |
| 2024Q3 | $2,407,622,972.00 |
| 2025Q1 | $2,406,073,279.00 |
| 2025Q2 | $2,408,338,872.00 |
| 2025Q3 | $2,409,295,102.00 |
Latest: $288.21B (2026Q2)
| Period | Value |
|---|---|
| 2020Q3 | $174.79B |
| 2020Q4 | $182.02B |
| 2021Q1 | $186.02B |
| 2021Q2 | $190.57B |
| 2021Q3 | $198.13B |
| 2021Q4 | $202.49B |
| 2022Q1 | $206.11B |
| 2022Q2 | $210.89B |
| 2022Q3 | $216.23B |
| 2022Q4 | $220.22B |
| 2023Q1 | $222.65B |
| 2023Q2 | $225.78B |
| 2023Q3 | $232.43B |
| 2023Q4 | $238.82B |
| 2024Q1 | $241.88B |
| 2024Q2 | $246.90B |
| 2024Q3 | $253.92B |
| 2024Q4 | $259.34B |
| 2025Q1 | $263.00B |
| 2025Q2 | $265.89B |
| 2025Q3 | $273.97B |
| 2025Q4 | $279.45B |
| 2026Q1 | $280.91B |
| 2026Q2 | $288.21B |
Latest results
Company History
Three brothers founded the company in New Brunswick, New Jersey, producing ready-to-use sterile surgical dressings with 14 employees.
Designed to support railroad workers far from medical care, including antiseptic supplies and field use directions.
Earle Dickson combined adhesive tape and gauze to create the first commercial adhesive bandage, sold starting 1921.
Robert Wood Johnson wrote
Cyanide-laced Tylenol led to a nationwide recall of 31 million bottles; company response set industry standards for crisis management.
$30 billion deal, the largest in company history, expanding pharmaceutical capabilities.
$16.6 billion purchase of cardiovascular medical technology company to bolster MedTech segment.
Consumer health division went public as Kenvue in May 2023, with J&J retaining minimal stake by 2024.
Acquired Intra-Cellular Therapies for $14.6B in January 2025, continuing aggressive M&A strategy.
Key Players
showing 6 of 21
The CEO view — 5 podcasts, interviews & articles →
Similar stocks in Healthcare
Funds we follow holding JNJ
By latest reported 13F position value. Market value at quarter-end, not cost basis.
